Welcome to the new beta version of legal500.com Visit the legacy site

North America - United States • Intellectual property

Jones Day

More informationMore information

With a focus on intellectual property transactions in the high-tech (including AI), fintech, biotech and pharmaceutical industries, Jones Day‘s IP transaction department covers the development, licensing, acquisition, and commercialization of key technology and intellectual property assets. The US group is led by Ka-On Li in Silicon Valley, who focuses on commercial and licensing transactions for clients active in industries such as technology, life sciences and financial services and advise son outsourcing, IP commercialization, as well as software- and cloud-related matters. In San Diego, Thomas Briggs has vast experience negotiating cross-border licensing arrangements, while Robert Latta focuses on IP matters relating to the life sciences and environmental sustainability spaces. In New York, Warren Nachlis' practice covers a range of IP-related matters and particularly centers on the pharmaceutical and biotechnology industries, and Scott Lyne focuses on corporate transactions, licensing, and counseling involving intellectual property and technology.

Legal 500 Editorial commentary

Key clients

  • ANSYS, Inc.
  • Asbury Automotive Group, Inc.
  • Astellas Pharma Inc.
  • Centre Lane Partners, LLC
  • Cibus Global, LLC
  • Incyte Corporation
  • J.F. Lehman
  • Labcorp
  • Meridian Bioscience, Inc.
  • Organon & Co.
  • restor3d, Inc.
  • Rich Data Corporation (Australia) Pty Ltd
  • Sanofi
  • Shanghai Junshi Biosciences Co., Ltd.
  • Sumitomo Pharma Co., Ltd.
  • VSE Corporation
  • Xyphos Biosciences, Inc.

Work highlights

  • Advised Xyphos Biosciences, Inc. in connection with a research collaboration and exclusive option license agreement with ImmunoPrecise Antibodies Ltd.
  • Advised Sanofi in connection with a Co-Development, Co-Commercialization & License Agreement with Johnson & Johnson's Janssen Pharmaceuticals relating to the development and commercialization of vaccines for extra-intestinal pathogenic E.coli.
  • Advised Incyte Corporation on its collaboration and license agreement with CMS Aesthetics Limited for the development and commercialization of ruxolitinib cream.

Lawyers

Leading partners

The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.

Practice head

The lawyer(s) leading their teams.

Ka-on Li

Other key lawyers

Thomas Briggs, Warren Nachlis, Robert Latta, Scott Lyne